We present the case of a 60-year-old man with unresectable cutaneous squamous cell carcinoma (cSCC) of the sternal area, which was not amenable to radiation therapy. The treatment history of this patient is remarkable as the disease had progressed through all lines of conventional therapy established in the literature. We decided to initiate treatment with epidermal growth factor receptor (EGFR) inhibitor cetuximab and we reassessed the patient after 12 weeks with a whole-body CT scan, documenting stability in the size and radiologic features of the disease. Cetuximab, like all current treatments for advanced cSCC, is administered off-label and proved effective in preventing further progression of disease in our patient.
Case report. cetuximab use in advanced cutaneous squamous cell carcinoma resistant to chemotherapy [version 1; peer review. 1 approved with reservations] / Sernicola, A.; Lampitelli, S.; Grassi, S.; Richetta, A. G.; Calvieri, S.. - In: F1000RESEARCH. - ISSN 2046-1402. - 8:(2019). [10.12688/f1000research.19149.2]
Case report. cetuximab use in advanced cutaneous squamous cell carcinoma resistant to chemotherapy [version 1; peer review. 1 approved with reservations]
Sernicola A.;Lampitelli S.;Richetta A. G.
;Calvieri S.
2019
Abstract
We present the case of a 60-year-old man with unresectable cutaneous squamous cell carcinoma (cSCC) of the sternal area, which was not amenable to radiation therapy. The treatment history of this patient is remarkable as the disease had progressed through all lines of conventional therapy established in the literature. We decided to initiate treatment with epidermal growth factor receptor (EGFR) inhibitor cetuximab and we reassessed the patient after 12 weeks with a whole-body CT scan, documenting stability in the size and radiologic features of the disease. Cetuximab, like all current treatments for advanced cSCC, is administered off-label and proved effective in preventing further progression of disease in our patient.File | Dimensione | Formato | |
---|---|---|---|
Case report.pdf
accesso aperto
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Creative commons
Dimensione
1.09 MB
Formato
Adobe PDF
|
1.09 MB | Adobe PDF |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.